AstraZeneca’s Voydeya Gets US FDA Approval As Add On To Ultomiris And Soliris
FDA approved the oral Factor D inhibitor for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemolgobinuria (PNH).

FDA approved the oral Factor D inhibitor for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemolgobinuria (PNH).